• Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.

      Churchyard, Gavin; Cárdenas, Vicky; Chihota, Violet; Mngadi, Kathy; Sebe, Modulakgotla; Brumskine, William; Martinson, Neil; Yimer, Getnet; Wang, Shu-Hua; Garcia-Basteiro, Alberto L; et al. (2021-08-24)
      Between November 2016 and November 2017, 4027 participants were enrolled; 4014 were included in the analyses (median age, 41 years; 69.5% women; all using antiretroviral therapy). Treatment completion in the first year for the combined rifapentine-isoniazid groups (n = 3610) was 90.4% versus 50.5% for the isoniazid group (n = 404) (risk ratio, 1.78 [95% CI, 1.61 to 1.95]). Tuberculosis incidence among participants receiving the rifapentine-isoniazid regimen twice (n = 1808) or once (n = 1802) was similar (hazard ratio, 0.96 [CI, 0.61 to 1.50]).